Medpace (NASDAQ:MEDP) CEO Sells $2,480,120.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 4,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $620.03, for a total value of $2,480,120.00. Following the completion of the transaction, the chief executive officer directly owned 540,544 shares of the company’s stock, valued at $335,153,496.32. This represents a 0.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Medpace Stock Down 1.8%

MEDP opened at $600.65 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The stock has a market cap of $16.77 billion, a PE ratio of 35.21, a PEG ratio of 2.68 and a beta of 1.15. The business has a 50 day moving average of $565.33 and a 200-day moving average of $494.55.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MEDP shares. Royal Bank Of Canada upped their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Mizuho boosted their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and raised their target price for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Finally, BMO Capital Markets lifted their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $584.18.

Institutional Trading of Medpace

Several institutional investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC raised its stake in shares of Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after buying an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in Medpace in the 2nd quarter worth about $296,000. Finally, M&T Bank Corp raised its position in Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after buying an additional 31 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.